DrugPatentWatch Database Preview
Mallinckrodt Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for MALLINCKRODT INC, and when can generic versions of MALLINCKRODT INC drugs launch?
MALLINCKRODT INC has four approved drugs.
There are thirteen US patents protecting MALLINCKRODT INC drugs.
There are forty-seven patent family members on MALLINCKRODT INC drugs in twenty countries and forty-seven supplementary protection certificates in seven countries.
Summary for Mallinckrodt Inc
| International Patents: | 47 |
| US Patents: | 13 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
| Drug Master File Entries: | 67 |
Drugs and US Patents for Mallinckrodt Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Inc | METHADONE HYDROCHLORIDE | methadone hydrochloride | POWDER;FOR RX COMPOUNDING | 006383-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,377,453 | Start Trial | Y | Start Trial | |||
| Mallinckrodt Inc | METHADONE HYDROCHLORIDE | methadone hydrochloride | POWDER;FOR RX COMPOUNDING | 006383-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,741,885 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mallinckrodt Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | 6,488,962 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MALLINCKRODT INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 7.5 mg/325 mg | ➤ Subscribe | 2014-04-03 |
Premature patent expirations for MALLINCKRODT INC
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| Start Trial | Start Trial |
International Patents for Mallinckrodt Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1152469 | Start Trial |
| Mexico | PA02012614 | Start Trial |
| Australia | 2001239893 | Start Trial |
| Australia | 2009223061 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mallinckrodt Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2822954 | LUC00083 | Luxembourg | Start Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| 1259550 | 08C0052 | France | Start Trial | PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725 |
| 1856135 | CA 2020 00018 | Denmark | Start Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| 0788511 | SPC/GB08/036 | United Kingdom | Start Trial | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
